Anifrolumab in Systemic Lupus Erythematosus with severe hematologic manifestations: an international multicentre study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #253; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "*JAK inhibitors administered were Baricitinib, Ruxolitinib and Upadacitinib. ANI can be a safe and effective treatment in SLE patients with severe hematological involvement, irrespective of other domains involved, contributing to maintain remission or low disease activity, and facilitating PDN tapering. Table 1. Baseline clinical characteristics and activity indices before and after anifrolumab therapy in the included patients."
Clinical • Aplastic Anemia • Atypical Hemolytic Uremic Syndrome • Autoimmune Hemolytic Anemia • Hemophagocytic lymphohistiocytosis • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Influenza • Leukopenia • Lupus • Musculoskeletal Diseases • Nephrology • Rare Diseases • Respiratory Diseases • Systemic Lupus Erythematosus • Thrombocytopenia • Thrombocytopenic Purpura • Varicella Zoster • IFNAR2
|
|
Adrián Mayo-Juanatey1; Paula David2; Shada Azem2; Merav Lidar3; Rahma Elziaty4; Büşra Köksoy5; Abdulsamet Erden6; Alessia Alunno7; Francesco Carubbi7; Agnieszka Cieplucha8; Joanna Makowska8; Fulvia Ceccarelli9; Fabrizio Conti9; Santos Castañeda10; Anahy Maria Brandy-Garcia11; Alessandro Conforti12; Ana Pareja13; Gaafar Ragab14; Antonella Laria15; Álvaro Sevilla-Ortega16; Mohammad Yassine Cherif17; Federica Maiolini18; Ilaria Mormile19; Vanesa Calvo20; Miriam Retuerto Guerrero21; Marta aguilar22; Marta Garijo Bufort23; María Andreo-Galera24; Samar Tharwat25; Ruben Darío Mantilla Hernández26; Marina Salido Olivares27; Juan José Alegre Sancho1
|